title: Effect of famotidine on recurrent bleeding after successful endoscopic treatment of bleeding peptic ulcer.
abstract: OBJECTIVE
  We investigated the effect of acid suppression therapy on recurrent bleeding after successful endoscopic treatment of bleeding peptic ulcer.
  
  
  METHODS
  A total of 400 patients with bleeding peptic ulcer received either intravenous infusion of famotidine (40 mg/day) (n = 207, 163 males, 44 females, mean age 61.5 years) or drip infusion of omeprazole (40 mg/day; n = 193, 134 males, 59 females, mean age 59.8 years) after successful endoscopic treatment. The fasting duration, hospital stay, volume of transfused blood, incidence of rebleeding and mortality were compared between the two groups.
  
  
  RESULTS
  The incidence of rebleeding did not differ significantly between the famotidine group (9%) and the omeprazole group (8%). The mean hospital stay was significantly shorter in the omeprazole group (18.4 days) than in the famotidine group (21.5 days, P = 0.009). However, there was no statistically significant difference in fasting duration, volume of transfused blood or mortality.
  
  
  CONCLUSIONS
  Our findings indicate that intravenous infusion of famotidine after successful endoscopic treatment is equivalent to drip infusion of omeprazole for prevention of recurrent bleeding.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Matsushima, Kurashiki, Japan. tkamada@med.kawasaki-m-ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Kamada
authors.forename: J
authors.initials: J
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Kusunoki
authors.forename: S
authors.initials: S
authors.lastname: Kido
authors.forename: H
authors.initials: H
authors.lastname: Hamada
authors.forename: R
authors.initials: R
authors.lastname: Aoki
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.forename: K
authors.initials: K
authors.lastname: Komoto
authors.forename: H
authors.initials: H
authors.lastname: Todo
authors.forename: M
authors.initials: M
authors.lastname: Sumioka
authors.forename: T
authors.initials: T
authors.lastname: Tanimoto
authors.forename: E
authors.initials: E
authors.lastname: Sanuki
authors.forename: K
authors.initials: K
authors.lastname: Sumii
authors.forename: H
authors.initials: H
authors.lastname: Ogoshi
authors.forename: T
authors.initials: T
authors.lastname: Hidaka
authors.forename: Q
authors.initials: Q
authors.lastname: Dongmei
authors.forename: K
authors.initials: K
authors.lastname: Chayama
authors.forename: K
authors.initials: K
authors.lastname: Haruma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001803:Blood Transfusion; D016099:Endoscopy, Gastrointestinal; D015738:Famotidine / Q000008:administration & dosage*; D005260:Female; D016558:Hemostasis, Endoscopic; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D010438:Peptic Ulcer Hemorrhage / Q000517:prevention & control* / Q000601:surgery; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000863:Antacids; D000897:Anti-Ulcer Agents; D015738:Famotidine; D009853:Omeprazole